Titre :
|
Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients.
|
Revue :
|
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus, Epub
|
Auteurs :
|
Brignol TN, Auteur ;
Fort PE ;
Ventura DF ;
Tadayoni R ;
Rendon A
|
Type de document :
|
Article
|
Année de publication :
|
26/09/2018
|
Langues:
|
Anglais
|
Mots-clés :
|
cataracte
;
corticoïde
;
corticothérapie
;
déflazacort
;
dystrophie musculaire de Duchenne
;
dystrophinopathie
;
effet indésirable
;
facteur de risque
;
ophtalmologie
;
prednisone
;
pression intraoculaire
;
prévalence
;
prise en charge ophtalmologique
|
Mots-clés:
|
cataracte
corticoïde
corticothérapie
déflazacort
dystrophie musculaire de Duchenne
effet indésirable
étude rétrospective
facteur de risque
glucocorticoïde
maladie ophtalmologique
ophtalmologie
prednisone
pression intraoculaire
prévalence
prise en charge ophtalmologique
|
Résumé :
|
To the Editor: We read with interest the recent article by Rice and colleagues1 reporting on 596 patients with Duchenne muscular dystrophy (DMD) treated with steroid and evaluated for cataract development. The authors reported that the prevalence of cataracts was 25.1% in patients receiving deflazacort compared with 12.6% of those on prednisone. Only 7 patients (1.4%) required cataract surgery at a mean age of 16.9 years, and all of them were on deflazacort. Although, as pointed out by the authors, this suggests a link between steroid administration and cataract development, a potential influence of the position of the DMD gene mutation cannot be excluded...
|
Pubmed / DOI :
|
Pubmed : https://www.ncbi.nlm.nih.gov/pubmed/?term=30266609
|
En ligne :
|
http://www.ncbi.nlm.nih.gov/pubmed/30266609
|
Voir aussi :
|
|